Company News

Avicanna Inc. (" Avicanna " or the " Company ") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce that all of management's nominees listed in the Company's management information circular dated July 28, 2022 (the " Circular ") were elected as directors of the Company at Avicanna's annual general and special meeting of shareholders held on August 31, 2022 (the " Meeting ").

The detailed results of the vote for the election of directors held at the Meeting are set out below.

Name of
Nominee
Votes cast
FOR
% votes cast
FOR
Votes
WITHHELD
% votes
WITHHELD
Dr. Chandrakant
Panchal
12,443,199 99.58% 52,408 0.42%
Aras
Azadian
12,461,654 99.73% 33,953 0.27%
Giancarlo
Davila Char
12,471,654 99.81% 23,953 0.19%
Eileen
McCormack
12,476,375 99.85% 19,232 0.15%
John
McVicar
12,473,154 99.82% 22,453 0.18%

At the Meeting, the Company's shareholders also approved: (i) fixing the number of directors for the ensuing year at five and empowering the board of directors of the Company to adjust such number between shareholder meetings by way of resolution in accordance with the Company's constating documents; (ii) the reappointment of Kingston Ross Pasnak LLP as the Company's auditors for the ensuing year and authorized the board of directors to fix the auditors' remuneration; and (iii) the unallocated awards under the omnibus long-term incentive plan of the Company.

Assad Kazeminy, PhD voluntarily retiring as a director did not stand for election.

About Avicanna Inc.

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development that has led to the commercialization of more than thirty products across various market segments:

Medical Cannabis & Wellness Products: Marketed under the RHO Phyto™ brand these medical and wellness products are a line of pharmaceutical-grade cannabinoid products containing varying ratios of cannabidiol ("CBD") and tetrahydrocannabinol ("THC"). The product portfolio contains a full formulary of products including oral, sublingual, topical, and transdermal deliveries that have controlled dosing, enhanced absorption and stability studies supported by pre-clinical data. The formulary is marketed with consumer, patient and medical-community education and training.

Pharmaceutical Pipeline: Leveraging Avicanna's scientific platform, vertical integration, and real-world evidence, Avicanna has created a pipeline of patent-pending drug candidates that are indication-specific and in various stages of clinical development and commercialization. These cannabinoid-based drug candidates look to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders. Avicanna's first pharmaceutical preparation (Trunerox™) is in the drug registration stage in South America.

SOURCE Avicanna Inc.

Stay Connected

For more information about Avicanna, visit www.Avicanna.com, contact Ivana Maric by email at info@avicanna.com or follow us on social media on LinkedIn, Twitter, Facebook or Instagram.

The Company posts updates through videos from the official Company YouTube channel.

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains "forward-looking information" within the meaning of applicable securities laws. Forward-looking information contained in this news release may be identified by the use of words such as, "may", "would", "could", "will", "likely", "expect", "anticipate", "believe, "intend", "plan", "forecast", "project", "estimate", "outlook" and other similar expressions. Forward-looking information contained in this news release includes, without limitation, statements related to Canadian commercialization efforts, international commercialization, R&D, financials, statements with respect to the Company's future business operations, the opinions or beliefs of management and future business goals. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company's annual information form dated March 31, 2022 filed with the Canadian securities regulators and available under the Company's profile on SEDAR at www.sedar.com. The statements in this news release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

AVCN:CA
Avicanna Expands its Epilepsy Research Program with a New Collaboration with the University of Toronto

Avicanna Expands its Epilepsy Research Program with a New Collaboration with the University of Toronto

Dr. Mac Burnham's team will explore Avicanna's drug candidate and its proprietary combination of cannabinoids in pre-clinical model for seizures.

Avicanna further expands its current research and commercial focus in Epilepsy which is supported by current medical cannabis sales and on-going research with UHN

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avicanna Reports Q2 2022 Financial Statement

Avicanna Reports Q2 2022 Financial Statement

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS

Avicanna Inc. (" Avicanna " or the " Company ") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce the filing of its interim financial statements for the three-month period ending June 30, 2022 (" Q2 2022 ").

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avicanna and Ei. Ventures Enter into an Agreement to Develop and Commercialize Adaptogen Nutraceuticals

Avicanna and Ei. Ventures Enter into an Agreement to Develop and Commercialize Adaptogen Nutraceuticals

Psilly™ branded functional fungi-based products will be developed by Avicanna utilizing Avicanna's proprietary delivery systems and scientific platform

Avicanna Inc. (" Avicanna " or the " Company" ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce that the Company has entered into an Intellectual Property Licensing & Royalty Agreement (" IPLRA ") with Ei.Ventures, Inc. ("Ei.") to develop and commercialize functional fungi-based products.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avicanna Announces Date of Upcoming Annual General and Special Meeting of Shareholders

Avicanna Announces Date of Upcoming Annual General and Special Meeting of Shareholders

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS

Avicanna Inc. (" Avicanna " or the " Company ") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is pleased to announce that its annual general and special meeting of shareholders will be held virtually on August 31, 2022 at 10:30 AM (Toronto Time) (the " Meeting ").

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avicanna Completes its First Commercial Export of its Derma-Cosmetics Brand Pura H&W into the European Union

Avicanna Completes its First Commercial Export of its Derma-Cosmetics Brand Pura H&W into the European Union

The exclusive distribution agreement with Bio-Gate AG includes 5 SKUs from Pura H&W's evidence-based derma-cosmetics portfolio

Initial portfolio launch is planned for Germany, Austria, and Switzerland in Q3 2022

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Curaleaf to Report Third Quarter 2022 Financial and Operational Results

Curaleaf Holdings, Inc. (CSE: CURA OTCQX: CURLF) ("Curaleaf" or the "Company") a leading international provider of consumer products in cannabis, today announced that it will report its financial and operating results for the second quarter ended September 30, 2022 after market close on November 7, 2022 .

Management will host a conference call and audio webcast that evening at 5:00 p.m. ET consisting of prepared remarks followed by a question and answer session related to the Company's operational and financial highlights.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Curaleaf Completes Acquisition of Tryke Companies

Bolsters Company's Presence in Three Key Growth Markets of Arizona , Nevada and Utah

Expands Curaleaf's Operations to 29 Cultivation Sites and 144 Dispensaries Nationwide

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Trulieve Announces October 2022 Event Participation

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced planned participation in upcoming conferences and events in October.

Trulieve logo (PRNewsfoto/Trulieve Cannabis Corp.)

  • Alliance Global Partners Virtual Consumer Cannabis Conference, October 4, 2022 : President Steve White will participate in a fireside chat and investor meetings.
  • Arcview Access Cannabis Investment Summit, October 20, 2022 : Founder and CEO Kim Rivers will participate in a panel discussion.

Information about our events, links to events where available, and slide presentations can be found at:
https://investors.trulieve.com/events-presentations

About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with established hubs in the Northeast, Southeast, and Southwest, anchored by leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com .

Facebook: @Trulieve
Instagram: @Trulieve _
Twitter: @Trulieve

Investor Contact
Christine Hersey , Executive Director of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com

Media Contact
Rob Kremer , Executive Director of Corporate Communications
+1 (404) 218-3077
Robert.Kremer@Trulieve.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/trulieve-announces-october-2022-event-participation-301638626.html

SOURCE Trulieve Cannabis Corp.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/October2022/03/c6205.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Trulieve to Open New Dispensary in Sierra Vista, Arizona

Grand opening on Oct. 1 with celebratory events on Oct. 8

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States today announced the opening of a new location at 1633 S. Highway 92, Sierra Vista, Arizona . The new adult-use only dispensary will open its doors at 9 a.m. on Saturday Oct. 1, with ongoing hours of 9 a.m. to 7 p.m. daily.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
cannabis plant

Cannabis Stocks: 10 Biggest Companies in 2022

The cannabis stock market offers investors the opportunity to get exposure to a revolutionary drug sector.

Although there's been major upheaval in the world of cannabis investments, with the current landscape at times showing stories of difficulty and losses, experts remain bullish on the long-term progress of the global market.

As laws and perspectives surrounding cannabis continue to change across jurisdictions, investors interested in this fast-moving industry will want to keep an eye on the progress of the cannabis stock universe.

Keep reading...Show less

Green Thumb Industries to Hold Third Quarter 2022 Earnings Conference Call on November 2, 2022

Green Thumb Industries Inc. (Green Thumb) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of RISE Dispensaries today announced it will release third quarter financial results after the market closes on Wednesday, November 2, 2022.

A conference call and audio webcast will also be held on Wednesday, November 2, 2022, at 5:00 p.m. Eastern Time/4:00 p.m. Central Time to discuss the results and answer any questions.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×